 HOUSTON--BUSINESS WIRE--Kiromic Biopharma, Inc. Nasdaq: KRBP, a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the planned resubmission of two investigational new drug IND applications with the U.S. Food and Drug Administration FDA. The revised INDs will be for first in-human dosing of our Off-the-Shelf, Allogenic Gamma-Delta T cell therapy for metastatic 